NHS cancer jab could save patients hours in hospital
SkimNews Take
The shift to rapid, injectable treatments for common cancers demonstrates how pharmaceutical delivery methods, not just new drug discovery, can significantly impact healthcare system capacity and patient experience.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NHS England will replace hour‑long Keytruda infusions with a one‑minute injection, slashing administration time to a couple of minutes.
- Shirley Xerxes, an 86‑year‑old patient at Mount Vernon Cancer Centre, said the new jab took “minutes instead of an hour” and let her return to gardening.
- Prof Peter Johnson, NHS England’s national clinical director for cancer, says the switch frees chemotherapy unit space and opens the door to community‑based treatment.
- Keytruda (pembrolizumab) currently treats 14 cancer types and is started in about 14,000 English patients each year; the injectable version will be given every three weeks (1‑min) or six weeks (2‑min).
- Opdivo (nivolumab) became the second NHS immunotherapy jab last year, paving the way for the third, Keytruda.
Why it matters: 14,000 English cancer patients will shave up to an hour from each treatment, freeing NHS staff and chemotherapy bays for other care, and enabling community‑based delivery that could reduce hospital overhead.
Ask SkimNews
